Adlai Nortye Ltd.
A clinical-stage biopharma firm developing cancer immunotherapies and RAS-targeting drugs.
ANL | US
Overview
Corporate Details
- ISIN(s):
- US00704R1095
- LEI:
- Country:
- United States of America
- Address:
- 685 U.S. HIGHWAY ONE, 2ND FLOOR, 8902 NORTH BRUNSWICK
- Website:
- https://www.adlainortye.com/
- Sector:
- Manufacturing
Description
Adlai Nortye Ltd. is a global clinical-stage biopharmaceutical company focused on discovering and developing innovative cancer therapies. The company's pipeline is centered on two key areas: next-generation cancer immunotherapies and RAS-targeting therapies. Its immunotherapy candidates include AN8025, a tri-functional fusion protein designed as a T-cell and antigen-presenting cell modulator, and AN4005, an oral small-molecule PD-L1 inhibitor. For RAS-driven cancers, the company is advancing AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting antibody-drug conjugate (ADC) that delivers a potent pan-RAS(ON) inhibitor.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Adlai Nortye Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Adlai Nortye Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Adlai Nortye Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
